Trade
Trading Type
Spot
Trade crypto freely
Alpha
Points
Get promising tokens in streamlined on-chain trading
Pre-Market
Trade new tokens before they are officially listed
Margin
Magnify your profit with leverage
Convert & Block Trading
0 Fees
Trade any size with no fees and no slippage
Leveraged Tokens
Get exposure to leveraged positions simply
Futures
Futures
Hundreds of contracts settled in USDT or BTC
Options
HOT
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
Investment
Simple Earn
VIP
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Quant Fund
VIP
Top asset management team helps you profit without hassle
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-Stop Lending Hub
VIP Wealth Hub
New
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Staking
Stake cryptos to earn in PoS products
BTC Staking
HOT
Stake BTC and earn 10% APR
GUSD Minting
New
Use USDT/USDC to mint GUSD for treasury-level yields
Soft Staking
Earn rewards with flexible staking
More
- Trending TopicsView More
79K Popularity
131.7K Popularity
248K Popularity
167.2K Popularity
18.1K Popularity
- Pin
Research on the weight loss drug CagriSema by Noor and Noord
On February 5th, Jinshi Data reported that Novo Nordisk (NVO.N) stated on Wednesday that its new trial of the next generation obesity drug CagriSema will focus on dose escalation and the duration of the trial to further demonstrate the potential of the drug. In December of last year, the data of the drug disappointed the market, causing the company's stock price to fall by 27%, which was one of the largest single-day declines for a European company. The CEO, Jorgensen, said that the company has confidence in the biological characteristics of this drug and is encouraged by what they see in the data.